Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy
Saved in:
Main Authors: | Luciano J. Costa, Eva Medvedova, Binod Dhakal, Bhagirathbhai R. Dholaria, Kelly N. Godby, Susan Bal, Gayathri Ravi, Smith Giri, Saurabh Chhabra, Rebecca Silbermann, Natalie S. Callander |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2025-02-01
|
Series: | Blood Cancer Journal |
Online Access: | https://doi.org/10.1038/s41408-025-01219-7 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
by: Manisha Bhutani, et al.
Published: (2025-02-01) -
Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple Myeloma
by: Benjamin A. Derman, et al.
Published: (2018-01-01) -
A Nomogram Based on Circulating Inflammatory Factors for Predicting Prognosis of Newly Diagnosed Multiple Myeloma Patients
by: Wang M, et al.
Published: (2025-02-01) -
Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf Countries
by: Anas Hamad, et al.
Published: (2024-07-01) -
Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma
by: Lawrence G Lum, et al.
Published: (2025-01-01)